KR20240015742A - 비알코올성 지방간 질환 및 비알코올성 지방간염 치료용 조성물 - Google Patents

비알코올성 지방간 질환 및 비알코올성 지방간염 치료용 조성물 Download PDF

Info

Publication number
KR20240015742A
KR20240015742A KR1020247002905A KR20247002905A KR20240015742A KR 20240015742 A KR20240015742 A KR 20240015742A KR 1020247002905 A KR1020247002905 A KR 1020247002905A KR 20247002905 A KR20247002905 A KR 20247002905A KR 20240015742 A KR20240015742 A KR 20240015742A
Authority
KR
South Korea
Prior art keywords
drug
ibutamoren
ghs
therapeutically effective
effective amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020247002905A
Other languages
English (en)
Korean (ko)
Inventor
마이클 올리버 토너
로이 쥐. 스미스
Original Assignee
루모스 파마, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 루모스 파마, 인크. filed Critical 루모스 파마, 인크.
Publication of KR20240015742A publication Critical patent/KR20240015742A/ko
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020247002905A 2018-02-14 2019-02-14 비알코올성 지방간 질환 및 비알코올성 지방간염 치료용 조성물 Ceased KR20240015742A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862630361P 2018-02-14 2018-02-14
US62/630,361 2018-02-14
PCT/US2019/017964 WO2019161025A1 (en) 2018-02-14 2019-02-14 Compositions for the treatment of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis
KR1020207023368A KR20200121308A (ko) 2018-02-14 2019-02-14 비알코올성 지방간 질환 및 비알코올성 지방간염 치료용 조성물

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020207023368A Division KR20200121308A (ko) 2018-02-14 2019-02-14 비알코올성 지방간 질환 및 비알코올성 지방간염 치료용 조성물

Publications (1)

Publication Number Publication Date
KR20240015742A true KR20240015742A (ko) 2024-02-05

Family

ID=67620042

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020247002905A Ceased KR20240015742A (ko) 2018-02-14 2019-02-14 비알코올성 지방간 질환 및 비알코올성 지방간염 치료용 조성물
KR1020207023368A Ceased KR20200121308A (ko) 2018-02-14 2019-02-14 비알코올성 지방간 질환 및 비알코올성 지방간염 치료용 조성물

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020207023368A Ceased KR20200121308A (ko) 2018-02-14 2019-02-14 비알코올성 지방간 질환 및 비알코올성 지방간염 치료용 조성물

Country Status (10)

Country Link
US (3) US20210059993A1 (cg-RX-API-DMAC7.html)
EP (3) EP4467158A3 (cg-RX-API-DMAC7.html)
JP (3) JP2021513552A (cg-RX-API-DMAC7.html)
KR (2) KR20240015742A (cg-RX-API-DMAC7.html)
CN (2) CN118453597A (cg-RX-API-DMAC7.html)
AU (2) AU2019222736B2 (cg-RX-API-DMAC7.html)
BR (1) BR112020016613A2 (cg-RX-API-DMAC7.html)
CA (1) CA3088177A1 (cg-RX-API-DMAC7.html)
EA (1) EA202091464A1 (cg-RX-API-DMAC7.html)
WO (1) WO2019161025A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020205498A1 (en) * 2019-03-29 2020-10-08 The General Hospital Corporation Ghrh or analogues thereof for use in treatment of hepatic disease
CA3192690A1 (en) * 2020-09-18 2022-03-24 Seung Yong Seong Pharmaceutical composition for treating nonalcoholic steatohepatitis and liver fibrosis
KR20220132312A (ko) 2021-03-23 2022-09-30 한국과학기술원 간세포의 IFN-γR1 매개 지질생성작용 억제를 통한 비알코올성 지방간 질환의 치료 방법
GEAP202516774A (en) 2022-11-03 2025-06-25 Lumos Pharma Inc Compactable oral formulations of ibutamoren
WO2025193784A1 (en) * 2024-03-12 2025-09-18 Lumos Pharma, Inc. Pharmaceutical formulations for maintaining lean muscle mass during weight loss treatment
WO2025217521A1 (en) * 2024-04-12 2025-10-16 Jnana Therapeutics Inc. Treating chronic kidney disease with a combination of a slc6a19 inhibitor and a glp-1 agonist
CN119405782A (zh) * 2025-01-06 2025-02-11 山东大学 胰岛素样生长因子结合蛋白-1在制备治疗非酒精性脂肪性肝病药物中的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL145106A0 (en) * 2000-08-30 2002-06-30 Pfizer Prod Inc Intermittent administration of a geowth hormone secretagogue
US20070123470A1 (en) * 2003-10-24 2007-05-31 Wladimir Hogenhuis Enhancement of growth hormone levels with a dipeptidyl peptidase IV inhibitor and a growth hormone secretagogue
JP2007532495A (ja) * 2004-04-07 2007-11-15 ガストロテック・ファルマ・アクティーゼルスカブ グレリン欠乏を治療するための分泌促進薬の使用
PE20100156A1 (es) * 2008-06-03 2010-02-23 Boehringer Ingelheim Int Tratamiento de nafld
US20090312302A1 (en) * 2008-06-17 2009-12-17 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating nonalcoholic fatty liver disease-associated disorders
AU2015314830B2 (en) * 2014-09-12 2021-01-07 Tobira Therapeutics, Inc. Cenicriviroc combination therapy for the treatment of fibrosis
RU2018113437A (ru) * 2015-09-16 2019-10-17 Тобира Терапьютикс, Инк. Комбинированная терапия с использованием ценикривирока для лечения фиброза
WO2019008554A1 (en) * 2017-07-06 2019-01-10 Conte Anthony METHOD FOR ORAL TREATMENT AND PREVENTION OF CARDIOVASCULAR DISEASE

Also Published As

Publication number Publication date
AU2019222736A1 (en) 2020-07-30
AU2019222736B2 (en) 2024-08-01
CN111727041A (zh) 2020-09-29
BR112020016613A2 (pt) 2020-12-22
JP2021513552A (ja) 2021-05-27
EA202091464A1 (ru) 2020-12-07
US20210059993A1 (en) 2021-03-04
EP4467158A2 (en) 2024-11-27
WO2019161025A1 (en) 2019-08-22
EP4623929A3 (en) 2025-12-17
EP3781158A4 (en) 2022-03-16
KR20200121308A (ko) 2020-10-23
AU2024205599A1 (en) 2024-08-22
US20230381158A1 (en) 2023-11-30
EP3781158A1 (en) 2021-02-24
CN118453597A (zh) 2024-08-09
EP4623929A2 (en) 2025-10-01
US20250281470A1 (en) 2025-09-11
EP4467158A3 (en) 2025-02-19
JP2025179056A (ja) 2025-12-09
CA3088177A1 (en) 2019-08-22
JP2024028337A (ja) 2024-03-04

Similar Documents

Publication Publication Date Title
US20230381158A1 (en) Compositions for the treatment of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis
CN1178696C (zh) 含人体生长激素和皮质甾醇合成抑制剂的用于治疗代谢综合症的制剂
JP2002501027A (ja) 高インスリン血症、高アンドロジェン症、高脂質血症および/または無排卵症を特徴とする代謝性疾患を処置するための、d型イノシトールを含む組成物
US20250241992A1 (en) Compositions and methods for treating metabolic diseases
US8071368B2 (en) Methods for promoting growth and survival of insulin-secreting cells
US20210121418A1 (en) Treatment of proteinuria
JP2022507644A (ja) Nafldおよびnashの併用治療
JP6890970B2 (ja) インスリン抵抗性を処置するためのhip/papタンパク質又はその誘導体の1種を含む組成物
Conti et al. Recombinant human insulin-like growth factor-1: a new cardiovascular disease treatment option?
HK40034973A (en) Compositions for the treatment of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis
Tulipano et al. Glucocorticoid inhibition of growth in rats: partial reversal with the full-length ghrelin analog BIM-28125
US20070037861A1 (en) Enhanced method of treatment of growth disorders
LIN et al. An open, phase III study of lanreotide (Somatuline PR®) in the treatment of acromegaly
US20260069586A1 (en) Methods for reducing weight and preserving or increasing tissue lean mass in patients suffering from cushing's syndrome
US20250235429A1 (en) Treatment of diseases via administration of buntanetap and an antidiabetic agent
US20250367218A1 (en) Methods of treating metabolic disorders and combination products for use in the same
WO2025193784A1 (en) Pharmaceutical formulations for maintaining lean muscle mass during weight loss treatment
WO2026063508A1 (ja) 医薬組成物
JP2025040825A (ja) 間質性肺炎を予防又は治療するための医薬及び医薬組成物
WO2026090181A1 (en) Glp-1 receptor agonist combinations and use thereof for increasing weight loss while improving muscle mass and strength
WO2026035940A1 (en) Treatment of obesity
TW202610632A (zh) 抗過量給藥的組合物及其用途
WO2025160184A1 (en) Methods for the prophylaxis and treatment of obesity and related conditions and disorders

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

B17 Application discontinued following pre-grant review

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B17-REX-PX0601 (AS PROVIDED BY THE NATIONAL OFFICE)

PX0601 Decision of rejection after re-examination

St.27 status event code: N-2-6-B10-B17-rex-PX0601

T11 Administrative time limit extension requested

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T11-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13 Administrative time limit extension granted

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T13-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

T13 Administrative time limit extension granted

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T13-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000